Teva’s new injection can use an existing sales base, but access still takes time

Original research record

What changed? Teva says the FDA approved WELTRUZA, a once-monthly schizophrenia injection, without a required post-injection monitoring period. It expects U.S. availability in the coming weeks. We connect that new product to the company’s existing UZEDY franchise, which generated $77 million in Q2 U.S. sales, up 43% from a year earlier. An established commercial base could help the launch, but this is our inference, not evidence of WELTRUZA orders. [Approval and availability](https://www.tevausa.com/news-and-media/press-releases/teva-announces-u.s.-food-and-drug-administration-fda-approval-of-weltruza-olanzapine-for-extended-re) [Existing product results](https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Delivers-Strong-Q2-Results-and-Raises-Outlook-for-All-Three-Key-Innovative-Brands-Reflecting-Continued-Execution-of-Its-Pivot-to-Growth-Strategy/default.aspx)

Behavioural fingerprint We computed 49 completed daily bars. TEVA rose 12.11% from 31 July to 8 October and 7.98% over 20 sessions, while the last five sessions were almost flat at −0.15%. The 14-session average true range was $1.22. At 15:39 EDT on 9 October, a separate research quote was $41.16, 4.87% above the prior close and 2.34% above the open, but 2.05% below the day high. The reaction is positive, with some fading already visible. It is not the frozen entry. [Numerical history](https://stockanalysis.com/stocks/teva/history/) The history crosses the 14 September one-for-one conversion from ADSs into ordinary shares. No economic price scaling is implied by that conversion. Our new call is strictly the NYSE ordinary-share quote in USD. [Completed conversion](https://www.sec.gov/Archives/edgar/data/818686/000119312526390562/d503082d8k.htm)

Historical comparables Our nine non-overlapping Friday-to-Friday comparisons contained seven rises and had a 1.00% median return, ranging from −2.41% to +5.10%. These are ordinary price windows, not nine drug approvals. They cannot tell us launch success or justify a 78% forecast. We have no matched after-hours approval study and no patient-start data.

Evidence graph OTR Database Data warned that approval and revenue run on different clocks. We add a specific bridge: a product that removes a monitoring requirement may be easier to deliver, while Teva’s existing injectable business provides experience in the same treatment area. The partner Medincell’s announcement concerns the same approval and is not an independent clinical experiment. Market prices measure investor response, not prescribing. [Partner announcement](https://www.medincell.com/medincell-achieves-major-milestone-with-u-s-fda-approval-of-weltruza-olanzapine/)

Opposing evidence Approval does not guarantee reimbursement, prescriber use or patient access. The medicine still carries important safety warnings, and European approval remains outstanding. Teva’s Q2 group sales fell 1% in dollars as weaker generics offset innovative-drug growth; one new product does not remove that broader pressure. Much of the immediate approval gain may already be priced. We are not making a clinical recommendation. [Product scope and warnings](https://www.tevausa.com/news-and-media/press-releases/teva-announces-u.s.-food-and-drug-administration-fda-approval-of-weltruza-olanzapine-for-extended-re) [Group results](https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Delivers-Strong-Q2-Results-and-Raises-Outlook-for-All-Three-Key-Innovative-Brands-Reflecting-Continued-Execution-of-Its-Pivot-to-Growth-Strategy/default.aspx)

Invalidation We would revisit this view if the launch is delayed, access terms are worse than expected or new safety information changes the business case. A sustained break below the $40.22 Friday opening would challenge the event-price support. The one-week horizon tests repricing of a clearer launch route; it does not promise measurable sales by then. Review conditions never change a frozen reference or resolution rule.

Bottom line We lean BULLISH over 168 elapsed hours. Frozen odds: 52% bullish / 29% bearish / 19% neutral, using an inclusive ±2% band. These are subjective, UNCALIBRATED estimates. We judge only the move after a fresh frozen reference. This is research, not personal investment advice. This call starts at the frozen issue shown below. Frozen issue: 2026-10-09T20:22:56.511Z; exact expiry: 2026-10-16T20:22:56.511Z. Reference: USD 41.25 (USD per ordinary share), source minute 2026-10-09T20:22:00.000Z. This is a provider research reference, not a verified user execution. Website publication time is separate.